Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401904 · ClinicalTrials.gov registry record · Phase 1
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04401904 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants.
The verdict
NCT04401904, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, blood pressure, and cardiac function. Based on these pleiotropic effects, including its calorie restriction-mimetic properties, the study team hypothesize that SGLT2 drugs will impact several basic aging-related processes, including reductions in oxidative damage to DNA and proteins, advanced glycation end products (AGE) and receptor for AGE (RAGE), cellular senescence, and mitochondrial function.
Interventions
- BEHAVIORAL Nutritional counseling
- DRUG Dapagliflozin 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401904
The ClinicalTrials.gov registry entry for NCT04401904 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nutritional counseling is the first listed.
NCT04401904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04401904 about?
NCT04401904 is a clinical study titled "SGLT2 Inhibition in Older Obese Adults With Pre-diabetes". Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, bl...
What is the current status of trial NCT04401904?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-06-25. Estimated completion is 2022-09-14.
What interventions are being tested in trial NCT04401904?
The interventions under investigation include: Nutritional counseling (BEHAVIORAL), Dapagliflozin 10 mg (DRUG).
Who is sponsoring clinical trial NCT04401904?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.